Form 4: Cumberland Pharmaceuticals Director Caroline Young Increases Stake Through 10b5-1 Trading Plan
SEC Form 4
Director Caroline Young continues to increase her holdings in Cumberland Pharmaceuticals through a pre-arranged Rule 10b5-1 trading plan.
Summary
- Caroline Young, a director of Cumberland Pharmaceuticals, has been consistently purchasing common stock through a pre-arranged Rule 10b5-1 trading plan.
- The purchases occurred on multiple dates in April 2025, with prices ranging from $4.01 to $5.12 per share.
- These transactions increased her direct holdings from 32,396 to 32,485 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The director's consistent buying suggests confidence, but it's within the confines of a pre-arranged plan, limiting the impact.
Positives
- The director's consistent purchases may signal confidence in the company's future prospects.
- The use of a 10b5-1 trading plan ensures compliance with insider trading regulations.
Industry Context
Director purchases are common and closely watched indicators of management sentiment. A 10b5-1 plan indicates a planned and consistent approach to stock acquisition, mitigating concerns about opportunistic trading based on inside information.
Stakeholder Impact
- The increased holdings by a director could be viewed positively by shareholders.
Key Dates
| Date | Description |
|---|---|
| 2024-11-14 | Date of adoption of Rule 10b5-1 trading plan |
| 2025-04-01 | First reported transaction date |
| 2025-04-02 | Reported transaction date |
| 2025-04-03 | Reported transaction date |
| 2025-04-04 | Reported transaction date |
| 2025-04-07 | Reported transaction date |
| 2025-04-08 | Reported transaction date |
| 2025-04-09 | Reported transaction date |
| 2025-04-10 | Reported transaction date |
| 2025-04-11 | Reported transaction date |
| 2025-04-14 | Reported transaction date |
| 2025-04-15 | Reported transaction date |
| 2025-04-16 | Reported transaction date |
| 2025-04-17 | Reported transaction date |
| 2025-04-21 | Reported transaction date |
| 2025-04-22 | Reported transaction date |
| 2025-04-23 | Reported transaction date |
| 2025-04-24 | Reported transaction date |
| 2025-04-25 | Reported transaction date |
| 2025-04-28 | Reported transaction date |
| 2025-04-29 | Reported transaction date |
| 2025-04-30 | Last reported transaction date |
| 2025-05-09 | Date of signature |
Keywords
Cumberland Pharmaceuticals, CPIX, Caroline Young, Director, Form 4, Beneficial Ownership, Rule 10b5-1, Insider Trading, Stock Purchase
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.